Logo

Supernus Reports the US FDA’s Acceptance to Review SPN-830’s Resubmitted NDA for the Treatment of Off Episodes in Parkinson’s Disease

Share this

Supernus Reports the US FDA’s Acceptance to Review SPN-830’s Resubmitted NDA for the Treatment of Off Episodes in Parkinson’s Disease

Shots:

  • The US FDA has accepted to review the resubmitted NDA of SPN-830, apomorphine infusion device, for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD) with the decision expected in Apr 2024
  • The NDA was resubmitted following the initial refusal to file (RTF) due to inadequate data, which had occurred after the original NDA submission in Sep 2020
  • The original NDA was based on data from the P-III (TOLEDO) trial that demonstrated a significant reduction in OFF time, with an improvement of 1.89hrs. per day vs PBO. These improvements were observed within 1wk. of initiating the therapy

Ref: Globenewswire | Image: Supernus

Related News:- Supernus to Acquire Adamas for ~$450M

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions